trastuzumab
FDA grants accelerated approval to fam-trastuzumab deruxtecan
In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast
เว็บไซต์ trastuzumab In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast trastuzumab A study of more than 4000 patients, published in 2014, showed that adding trastuzumab to chemotherapy led to a 37% relative improvement in
trastuzumab Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast Trastuzumab side effects · heart problems; · nausea, diarrhea, weight loss; · headache; · trouble sleeping, feeling tired; · low blood cell
ไม่สามารถโหลดการรับสินค้าได้ ความพร้อมใช้งาน
